Fermenta Board Approves Sale of Environmental Solutions Business to Wholly Owned Subsidiary

▴ Fermenta Biotech Limited
To enable specialized management and accelerated growth of environmental business vertical that includes waste management, water treatment, and bioremediation
Mumbai, 19 September 2025: Fermenta Biotech Limited, India's leading manufacturer of premium-grade APIs, intermediates, and nutritional premixes for the global markets, today announced that its Board of Directors has approved the sale of its environmental solutions business operations to a wholly owned subsidiary, Fermenta Environment Solutions Private Limited (FESPL) on a slump sale basis. This strategic business transfer, effective 1 October 2025, represents another important milestone in Fermenta's commitment to sustainable innovation and environmental stewardship and enhances operational focus both at parent and subsidiary level. Following this transfer the subsidiary will continue and expand the business of conceiving, designing, providing, and manufacturing for sale and distribution a wide range of environmental solutions. The subsidiary's comprehensive portfolio will include—but not be limited to—solid waste management, wastewater and water management, lake and pond bioremediation, fly ash handling, ground and soil remediation, oil sludge treatment, and air pollution management. Additionally, the entity will undertake the installation, operation, and maintenance of sewage treatment plants (STPs), water treatment plants (WTPs), and effluent treatment plants (ETPs), either independently or through strategic collaborations. This strategic move integrates scientific capability with sustainable development, positioning FESPL to address one of the most pressing challenges of our time—environmental resilience. The initiative also aligns with Fermenta’s vision to leverage its expertise and capabilities to create solutions that benefit both business and society. Comment from Prashant Nagre - Managing Director "The Board's approval for this slump sale transaction marks a significant step in our journey toward comprehensive sustainability leadership. By transferring our environmental solutions portfolio to a dedicated subsidiary, we are creating a focused entity that can accelerate growth and innovation in this critical sector. This structured approach will enable specialized management, enhanced operational efficiency, and targeted resource allocation at both parent and subsidiary levels. The transaction reflects Fermenta’s commitment to applying our decades-honed capabilities to address critical environmental challenges while creating long-term value for all stakeholders. This strategic move perfectly complements our core business and reinforces our strategy of sustainable innovation that benefits both business and society." About Fermenta Biotech Limited (www.fermentabiotech.com) delivers best-in-class, science-validated nutritional ingredients across pharmaceuticals, dietary supplements, food & beverage, veterinary, and animal nutrition industries. Our state-of-the-art manufacturing facilities located at Kullu (Himachal Pradesh), Dahej (Gujarat), and Tirupati (Andhra Pradesh), supported by the R&D Excellence Centre at Thane (near Mumbai) drive Fermenta's comprehensive portfolio of premium vitamins, nutritional premixes and ingredients that exceed the unique needs and stringent regulatory standards of over 400 discerning customers in more than 60 countries. With decades of expertise at global-scale complex manufacturing, Fermenta also provide research-based custom solutions in green chemistry, APIs & intermediates, and environmental solutions. Safe Harbour Statement Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, market opportunities, competitive positioning, slump sale transaction potential, the progress and results of research and development, potential project characteristics, project potential, and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements due to various factors including market conditions, regulatory changes, competitive dynamics, and other business risks. Fermenta Biotech Limited assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions, or other factors, except as and when required by applicable law.
Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Clinical Interventions in Chronic Hepatitis B and C: Antiviral Efficacy, Liver Fibrosis Scoring, and Monitoring August 11, 2026
Common Health Mistakes Indians Should Avoid: A Practical Guide to Everyday WellnessAugust 11, 2026
How to Build a Healthy Lifestyle After 40: A Practical Guide for Indian AdultsAugust 11, 2026
Milk Microbiome Could Hold New Clues to Lifelong Health, Experts SayAugust 10, 2026
Globally Renowned Dermatologist and Sesderma Founder Professor Dr. Gabriel Serrano to Visit India to Showcase Cutting-Edge Derma-Tech for Indian Skincare at Scientific Symposiums Hosted by Iberia PharmaceuticalsAugust 10, 2026
Sharda Hospital Celebrates World Breastfeeding Week with a Week-Long Awareness ProgrammeAugust 10, 2026
Swinburne University of Technology Opens Applications for Master of Engineering ScienceAugust 10, 2026
GLP-1 Receptor Agonists: A New Era in Weight Loss TreatmentAugust 10, 2026
Immunotherapy vs. Chemotherapy: Understanding the Mechanisms of Precision OncologyAugust 10, 2026
Mitigating Tech-Induced Ailments: Managing Screen Time, Sedentary Lifestyles, and Dry Eye SyndromeAugust 10, 2026
The Blueprint of Validation: Navigating Medical AI’s "Reckoning Year"August 10, 2026
The Future of Smart Hospitals: Redefining Healthcare Delivery in India August 10, 2026
Healthcare Data Security in India: Risks, Threats, and Best Practices for a Digital-First Health EcosystemAugust 10, 2026
The Science of Resilience: Psychological Strategies for Modern StressAugust 08, 2026
The Science of Fasting: 2026 Research on Autophagy and LongevityAugust 08, 2026
Early Markers of Insulin Resistance: Moving Beyond Fasting Blood SugarAugust 08, 2026
Healthcare Management Challenges in India: What Hospital Leaders Must Address NowAugust 08, 2026
Importance of Patient Safety: Why Every Hospital in India Must Prioritize ItAugust 08, 2026
Decoding Fatty Liver Disease: Symptoms, Reversibility, and the MASLD/NAFLD SpectrumAugust 07, 2026
Heart-Healthy Dietary Patterns: Translating Clinical Nutrition Guidelines into Daily MealsAugust 07, 2026